Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Vericel Stock Quote

Vericel (NASDAQ: VCEL)

$48.70
(1.7%)
$0.80
Price as of April 15, 2024, 4:00 p.m. ET

Vericel Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
VCEL +63.26% +199.51% +24.53% -96%
S&P +23.57% +76.22% +11.98% +541%

Vericel Company Info

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.